Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

pilaralisib

pilaralisib Structure
  • ₹0
  • Product name: pilaralisib
  • CAS: 934526-89-3
  • MF: C25H25ClN6O4S
  • MW: 541.02
  • EINECS:
  • MDL Number:MFCD26142605
  • Synonyms:PILARALISIB (XL147);SAR245408;XL 147;XL-147,Pilaralisib, SAR245408;XL147(pilaralisib);2-amino-N-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide;2-Amino-N-[3-[N-[3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide;Pilaralisib (XL-147);pilaralisib;Propanamide, 2-amino-N-[3-[[[3-[(2-chloro-5-methoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-2-methyl-
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Melting point :216-220oC
Density :1.458±0.06 g/cm3(Predicted)
storage temp. :Refrigerator
solubility :DMSO (Slightly)
pka :6.33±0.30(Predicted)
form :Solid
color :Light Yellow to Yellow

Safety Information

Symbol(GHS): GHS hazard pictogramsGHS hazard pictograms
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H302 Harmful if swallowed Acute toxicity,oral Category 4 Warning GHS hazard pictograms P264, P270, P301+P312, P330, P501
H372 Causes damage to organs through prolonged or repeated exposure Specific target organ toxicity, repeated exposure Category 1 Danger GHS hazard pictograms P260, P264, P270, P314, P501
Precautionary statements:
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P264 Wash hands thoroughly after handling.
P264 Wash skin thouroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P301+P312 IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P314 Get medical advice/attention if you feel unwell.
P330 Rinse mouth.
P501 Dispose of contents/container to..…

Description

The phosphatidylinositol 3-kinase (PI3K) signaling pathway has central roles in cell growth, development, and survival. Pilaralisib is a methylbenzenesulfonamide derivative that reversibly inhibits class I PI3Ks (IC50s = 39, 36, 23, and 383 nM for p110α, -δ, -γ, and -β, respectively). It has been shown to abrogate Akt and S6 kinase phosphorylation, reduce cyclin D1 and retinoblastoma protein, and upregulate the CDK inhibitor p27, inhibiting cell proliferation. In HER2-overexpressing breast cancer cells, cotreatment with the HER2 inhibitors trastuzumab or lapatinib are reported to sensitize tumor cells to the growth inhibitory effect of pilaralisib. This compound has been evaluated in clinical trials in patients with advanced solid tumors.